CLDN1 has been described as downregulated in luminal breast cancer, but upregulated in aggressive basal-like subtypes, which may potentially suggest subtype switching for cells expressing ESR1-YAP1 or other ER fusions (64). The gene discussed is CLDN1; the disease is breast carcinoma.